Phase I DSTP3086S Trial Results Published

November 11, 2019 | Media Relations

PCCTC study demonstrates safety and antitumor activity of humanized immunoglobulin G1 anti-STEAP1 monoclonal antibody DSTP3086S, supporting further development in metastatic castration-resistant prostate cancer.

Committed to world-class science!

Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.